BRPI0809926A2 - Composições imunogênicas compreendendo polipeptídios de mycobacterium tuberculosis e fusões dos mesmos - Google Patents

Composições imunogênicas compreendendo polipeptídios de mycobacterium tuberculosis e fusões dos mesmos

Info

Publication number
BRPI0809926A2
BRPI0809926A2 BRPI0809926-0A2A BRPI0809926A BRPI0809926A2 BR PI0809926 A2 BRPI0809926 A2 BR PI0809926A2 BR PI0809926 A BRPI0809926 A BR PI0809926A BR PI0809926 A2 BRPI0809926 A2 BR PI0809926A2
Authority
BR
Brazil
Prior art keywords
mergers
same
mycobacterium tuberculosis
immunogenic compositions
compositions understanding
Prior art date
Application number
BRPI0809926-0A2A
Other languages
English (en)
Inventor
Steven G Reed
Rhea N Coler
Gregory C Ireton
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of BRPI0809926A2 publication Critical patent/BRPI0809926A2/pt
Publication of BRPI0809926B1 publication Critical patent/BRPI0809926B1/pt
Publication of BRPI0809926B8 publication Critical patent/BRPI0809926B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
BRPI0809926A 2007-04-04 2008-04-04 composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora BRPI0809926B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91016907P 2007-04-04 2007-04-04
US60/910.169 2007-04-04
PCT/US2008/059500 WO2008124647A2 (en) 2007-04-04 2008-04-04 Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

Publications (3)

Publication Number Publication Date
BRPI0809926A2 true BRPI0809926A2 (pt) 2014-10-07
BRPI0809926B1 BRPI0809926B1 (pt) 2020-09-29
BRPI0809926B8 BRPI0809926B8 (pt) 2021-05-25

Family

ID=39620241

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809926A BRPI0809926B8 (pt) 2007-04-04 2008-04-04 composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora

Country Status (11)

Country Link
US (6) US8486414B2 (pt)
EP (2) EP2136836B8 (pt)
JP (3) JP5378350B2 (pt)
CN (2) CN101687027B (pt)
BR (1) BRPI0809926B8 (pt)
DK (1) DK2136836T3 (pt)
ES (1) ES2621211T3 (pt)
MX (2) MX2009010800A (pt)
PL (1) PL2136836T3 (pt)
WO (1) WO2008124647A2 (pt)
ZA (1) ZA200907316B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106536A2 (en) * 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2573107A1 (en) * 2011-09-21 2013-03-27 Norwegian Institute of Public Health A recombinant fusion protein
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN102586139B (zh) * 2012-01-20 2013-03-20 广东本科生物工程股份有限公司 一种高产ad/add的菌株及高效生产ad/add的方法
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
WO2013119763A1 (en) 2012-02-07 2013-08-15 Intuitive Biosciences, Inc. Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
US10048561B2 (en) 2013-02-21 2018-08-14 View, Inc. Control method for tintable windows
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
EP4299138A3 (en) * 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
CN102899334B (zh) * 2012-10-29 2015-02-25 英诺特（唐山）生物技术有限公司 一种结核分枝杆菌重组蛋白质及其制备方法
CN105025921B (zh) 2013-03-15 2019-02-19 宾夕法尼亚大学理事会 用于结核病的预防或治疗的合成免疫原
CN104237508B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
CN104237509B (zh) * 2013-06-19 2015-12-02 华中农业大学 一种结核分枝杆菌的检测试剂盒及应用
EP3013364B1 (en) * 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP6249712B2 (ja) * 2013-10-09 2017-12-20 公益財団法人ヒューマンサイエンス振興財団 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法
CN103698531B (zh) * 2013-11-25 2015-10-14 广东体必康生物科技有限公司 Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
KR101477795B1 (ko) * 2014-04-23 2015-01-02 건국대학교 산학협력단 Ａｄｋ 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
EP3231439A4 (en) * 2014-12-10 2018-01-24 Konkuk University Glocal Industry-Academic Collaboration Foundation Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia
RU2668160C1 (ru) * 2015-04-03 2018-09-26 Конкук Юниверсити Глоукал Индастри-Академик Коллэборейшн Фаундейшн Антибактериальная композиция, содержащая белок adk в качестве активного ингредиента, для борьбы с карбапенем-резистентными грамотрицательными бактериями
CN106645733A (zh) * 2015-07-16 2017-05-10 广东体必康生物科技有限公司 用于特异性检测结核分枝杆菌感染的蛋白
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
EP3458088A2 (en) * 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
US10428122B2 (en) 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
AU2017280065B2 (en) 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
AU2018285694B2 (en) 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CN107817228B (zh) * 2017-06-30 2022-06-14 四川农业大学 对E.coli O157:H7免酶及免荧光标记的检测方法
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2019079155A1 (en) * 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
US12195810B2 (en) 2017-12-22 2025-01-14 Massachusetts Eye And Ear Infirmary Comprehensive microbial panel for molecular diagnosis of eye infections
CA3098015A1 (en) 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN108411030B (zh) * 2018-05-25 2021-05-14 兰州大学 引物对及包含其的试剂盒、用途和检测蒺藜苜蓿生态型a17和r108的方法
CN108948175B (zh) * 2018-07-23 2020-11-20 首都医科大学附属北京胸科医院 与人类蛋白smad2相互作用的结核蛋白及其应用
JP2021535930A (ja) * 2018-09-17 2021-12-23 キュラティス インコーポレイティッド Ｓｔｉｎｇアゴニストを含む抗原性補強剤及びワクチン組成物
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
US20220204560A1 (en) * 2019-05-02 2022-06-30 L-Base Co., Ltd. Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
WO2020249756A1 (en) * 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
CN111286551A (zh) * 2020-01-04 2020-06-16 昆明理工大学 结核分枝杆菌的快速检测引物、试剂盒及其使用方法
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
CN113121703B (zh) * 2021-03-03 2023-04-25 上海晶诺生物科技有限公司 一种具有结核杆菌免疫原性的融合蛋白及其应用
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CN114150006B (zh) * 2021-11-29 2023-07-25 中国农业科学院植物保护研究所 一种可提高米尔贝霉素产量的基因簇、重组菌及其制备方法与应用
CN116284283A (zh) * 2021-12-13 2023-06-23 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
CN116694653B (zh) * 2022-02-28 2026-07-10 广州达安基因股份有限公司 一种嗜热栖热菌苹果酸脱氢酶重组基因及其制备方法和应用
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116041454B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因、应用
CN117402798A (zh) * 2023-07-25 2024-01-16 中国科学院微生物研究所 一种防治结核病的重组卡介苗药物
NL2036756B1 (en) * 2024-01-05 2024-08-29 Univ Shihezi Fluorescent pcr method for detecting listeria monocytogenes and mycobacterium tuberculosis in milk
CN118987197B (zh) * 2024-10-24 2025-01-24 山东第二医科大学 一种自佐剂型热稳定纳米多价结核疫苗及其制备方法与应用
WO2026108990A1 (zh) * 2024-11-21 2026-05-28 深圳瑞吉生物科技有限公司 一种防治结核病的mRNA药物组合物及其应用
CN121513181A (zh) * 2024-11-21 2026-02-13 深圳瑞吉生物科技有限公司 一种防治结核病的mRNA药物组合物及其应用
CN119823286B (zh) * 2025-01-16 2026-02-06 中国动物卫生与流行病学中心 一种重组蛋白抗原及其在制备用于检测牛伽马干扰素试剂盒中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4761180A (en) 1986-08-27 1988-08-02 Hewlett-Packard Company Dyes containing tetramethylammonium cation for ink-jet printing inks
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) * 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5359681A (en) * 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1484405A1 (en) 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20020081579A1 (en) 1998-02-13 2002-06-27 Jane E. R. Potter Method for the isolation of novel antigens
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
WO2003093307A2 (en) * 2002-04-27 2003-11-13 The Secretary Of State For Environment, Food And Rural Affairs Mycobacterial antigens and uses thereof
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
EP1786460A4 (en) 2004-08-26 2008-04-02 Sequella Inc TEST FOR DETECTION OF TUBERCULOSIS IN NON-MENTAL PRIMATES
WO2006026464A2 (en) * 2004-08-27 2006-03-09 Davidsen Kevin P Handclapping aid
US7968105B2 (en) * 2005-06-23 2011-06-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP2468300B1 (en) * 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof

Also Published As

Publication number Publication date
US20180170975A1 (en) 2018-06-21
CN104815324A (zh) 2015-08-05
BRPI0809926B8 (pt) 2021-05-25
WO2008124647A2 (en) 2008-10-16
EP3199176B1 (en) 2020-02-19
EP2136836B8 (en) 2017-04-12
JP2014058520A (ja) 2014-04-03
US8486414B2 (en) 2013-07-16
JP5922074B2 (ja) 2016-05-24
US20250304629A1 (en) 2025-10-02
CN101687027B (zh) 2015-01-28
JP5378350B2 (ja) 2013-12-25
DK2136836T3 (en) 2017-04-10
US12344641B2 (en) 2025-07-01
US11091521B2 (en) 2021-08-17
JP2010524854A (ja) 2010-07-22
ZA200907316B (en) 2013-03-27
PL2136836T3 (pl) 2017-07-31
EP2136836B1 (en) 2017-01-04
EP3199176A1 (en) 2017-08-02
US20220017578A1 (en) 2022-01-20
US20100129391A1 (en) 2010-05-27
EP2136836A2 (en) 2009-12-30
JP2016145209A (ja) 2016-08-12
US20130209500A1 (en) 2013-08-15
MX2009010800A (es) 2010-01-29
US9822152B2 (en) 2017-11-21
US20240140997A1 (en) 2024-05-02
ES2621211T3 (es) 2017-07-03
CN101687027A (zh) 2010-03-31
WO2008124647A3 (en) 2009-04-02
MX351247B (es) 2017-10-05
BRPI0809926B1 (pt) 2020-09-29
US11897922B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
EP2235090A4 (en) MULTIFUNCTIONAL FORMS OF POLYOXAZOLIN COPOLYMERS AND ACTIVE COMPOSITIONS THEREWITH
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
EP2153838A4 (en) ANTI-NOROVIRUS AGENT AND COMPOSITION THEREOF
DK1891953T3 (da) Sterile formuleringer og fremgangsmåder der modificerer immunresponset
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BRPI0910702A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
ZA200907316B (en) Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
DK2193097T3 (da) Nanostrukturforstærkede kompositartikler og fremgangsmåder
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
FR19C1066I2 (fr) Compositions ophtalmologiques et leur utilisation
EP2152663A4 (en) TRIARYL COMPOUNDS AND COMPOSITIONS THEREWITH
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
EP2371921A4 (en) BLOCK COPOLYMER COMPOSITION AND HOT MELTING LIQUID COMPOSITION
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
BRPI0815094A2 (pt) Ácidos nucleicos de ligação de sdf-1 e o uso dos mesmos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: INFECTIOUS DISEASE RESEARCH INSTITUTE (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO 870230044794 DE28/05/2023, E NECESSARIO MAIS UMA GRU 248 PARA ALTERACAO DE SEDE SOLICITADA NA PETICAO.

B25D Requested change of name of applicant approved

Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE (US)

B25G Requested change of headquarter approved

Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE (US)